ClinicalTrials.gg
CompletedNCT04279197Updated Jan 3, 2022

Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu

A Phase 2 interventional study of Fuzheng Huayu Tablet and Vitamin C tablets in Pulmonary Fibrosis Due to COVID-19, sponsored by ShuGuang Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-01-03.

Sponsored by ShuGuang Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 472 studies in COVID-19 with a site in China — 53 open to participants now, 75 under way, 8 of them phase 3. COVID-19 · China.

Enrollment
187th of 330
142 · median 200
Started
2020
with 122 others
Phase 2
48 of 472
4 open now
Registered
17th of 472
by date

Among the 472 studies in COVID-19 with a site in China, this one is the 187th largest by enrollment of the 330 interventional ones that give a count, is one of 123 that started in 2020, is one of 48 in phase 2, and was the 17th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

53 of the 472 studies in COVID-19 with a site in China are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 472 studies in COVID-19 with a site in China, or all of them as a file.
02

Study summary

According to previous studies, viral pneumonia can develop into pulmonary fibrosis, which can affect patients'lung function and even life health.This study aims to observe the efficacy and safety of Fuzheng Huayu Tablets in the treatment of pulmonary fibrosis after COVID-19.

Read the detailed description

The patients with COVID-19 could suffered from the pulmonary dysfunction and/or fibrosis the recovery period, but there are no certain drugs or treatment to cope with this situation. Our previous studies indicated that Fuzheng Huayu tablets (FZHY) could regress the lung fibrosis induced by bleomycin in animals, and improve the pulmonary function in the patients with chronic obstructive pulmonary disease. Now we design this trial to carry out the clinical study in order to evaluate the effects of Fuzheng Huayu tablets on pulmonary fibrosis and/or pulmonary function injury in the recovery period of COVID-19 and expect to improve the prognosis.

This is a randomized, double-blind, multicenter, placebo-controlled clinical trial.It enrolls 142 patients who had been diagnosed with COVID-19, but currently they are negative for viral testing and have developed pulmonary fibrosis or pulmonary dysfunction. They are randomly assigned into Placebo group and FZHY group. All patients are given usual treatment such as respiratory function rehabilitation training and vitamin C. The FZHY group is given Fuzheng Huayu tablets, and the control group is given placebo. Each patient will be observed for 24 weeks and followed up for 8 weeks. The primary outcomes for the trial are the improvement proportion of pulmonary fibrosis judged by HRCT score and the improvement of lung function(FVC,FEV1,FVC/FEV1). Secondary outcomes include six-minute walk distance, improvement proportion of pulmonary inflammation, improvement proportion of clinical symptoms , quality of Life-BREF (QOL-BREF) Score, patient health questionnaire-9 (PHQ-9) Score, general anxiety disorder-7 (GAD-7) score. The safety also be observed.

03

Conditions studied

  • Pulmonary Fibrosis Due to COVID-19
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria (I) Discharged patients fulfilling the diagnostic criteria of COVID-19 (China Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7); (II) COVID-19 RNA in respiratory specimens or blood specimens of patients is negative (>2 times), assayed by real-time fluorescent polymerase chain reaction test (RT-PCR); (III) Pulmonary CT scans within 7 days showed that there were still unabsorbed inflammation or pulmonary fibrosis in the lungs; (IV) Age 18-70.

Exclusion criteria

  • Patients who have undergone lung surgery that affects pulmonary function, such as pulmonary transplantation, pulmonary resection, pulmonary volume reduction, etc;
  • Relying on mechanical ventilation to maintain pulmonary function, such as ventilators;
  • Combined with chronic pulmonary diseases affecting pulmonary function, such as , other known causes of interstitial pulmonary disease;
  • Patients with diseases affecting cardiac function, such as pulmonary circulation hypertension, heart failure, peripheral vascular disease, fibromyalgia, and pacemaker installation;
  • Patients with severe underlying diseases affecting survival, including uncontroled cardiac, renal, digestive, hematological, neuropsychiatric, immune, metabolic diseases, malignant diseases and severe malnutrition;
  • Resting heart rate >120 times/min;
  • Systolic blood pressure > 180 mmHg, diastolic blood pressure > 100 mmHg;
  • Unstable angina pectoris or myocardial infarction occurring within the last month;
  • Severe obesity ( > 30 kg/m2);
  • Allergic constitution, allergic to the drug components involved in the treatment program;
  • Pregnant or breastfeeding women;
  • Patients with disabilities who are unable to complete the efficacy evaluation questionnaires;
  • Difficult collaborators with poor mental health status, suffering from mental illness, patients without self-control, unable to express clearly;
  • Those who are participating in other clinical trials;
  • According to the investigator's judgment, patients whose enrollment complications or poor compliance will affect the efficacy and safety evaluation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    FZHY Group

    usual treatment (respiratory function rehabilitation training + Vitamin C tablets) * Fuzheng Huayu tablets

    Drug: Fuzheng Huayu Tablet · Drug: Vitamin C tablets · Other: respiratory function rehabilitation training

  • Placebo comparator
    Placebo Group

    usual treatment (respiratory function rehabilitation training + Vitamin C tablets) * placebo

    Drug: Vitamin C tablets · Drug: Placebo · Other: respiratory function rehabilitation training

Interventions

  • DrugFuzheng huayuStudies of Fuzheng huayuFuzheng huayu pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.

    Also known as: FZHY

  • DrugAscorbic AcidStudies of Ascorbic AcidAscorbic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral;

    Also known as: VC

  • DrugPlacebo

    Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.

  • Otherrespiratory function rehabilitation training

    Health exercise, once a day

06

What researchers measure

Primary outcomes

  1. The improvement proportion of pulmonary fibrosis

    Evaluation of pulmonary fibrosis Improvement. pulmonary fibrosis judged by HRCT score.HRCT images are divided into four grades according to the score, and a reduction of one grade is an improvement.

    Time frame: Week 24

  2. The improvement of lung function

    FVC, FEV1, FVC/FEV1

    Time frame: Week 24

Secondary outcomes

  1. The improvement proportion of pulmonary inflammation

    Evaluation of pulmonary inflammation Improvement

    Time frame: Week 24

  2. The improvement proportion of clinical symptom

    Discomfort symptoms include dyspnea, cough, exhausted, fatigue, insomnia, sweating, poor appetite, diarrhea, etc., which are common manifestations of patients with COVID-19

    Time frame: Week 24

  3. Quality of Life-BREF (QOL-BREF)

    This scale can reflect the quality of life of patients to some extent.

    Time frame: Week 24

  4. Patient Health Questionnaire-9(PHQ-9)

    This scale can reflect the quality of life of patients to some extent.

    Time frame: Week 24

  5. Generalized anxiety disorder-7(GAD-7)

    This scale can reflect the quality of life of patients to some extent.

    Time frame: Week 24

  6. The 6-minute walk distance

    Evaluation of Lung Function Improvement

    Time frame: Week 24

07

Study locations

1 site
  • Shuguang Hospital
    Shanghai, Shanghai 201203, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Mar 2021, 11 months.

Of 359 non-industry phase 2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 11 months is close to that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2020
First posted
Feb 21, 2020
StartActual
Apr 23, 2020
Primary completionActual
Mar 24, 2021
CompletionActual
Mar 24, 2021
Last update
Jan 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04279197
Lead sponsor
ShuGuang Hospital
Collaborators
Hubei Hospital of Traditional Chinese Medicine, Jingmen No.1 People's Hospital, Wuhan No.1 Hospital, Wuhan Third Hospital, Huangshi Hospital of Traditional Chinese Medicine
Responsible party
Liu Chenghai (Institute Director, ShuGuang Hospital) — Principal investigator
First posted
Feb 21, 2020
Start date
Apr 23, 2020
Primary completion
Mar 24, 2021
Completion
Mar 24, 2021
Last update
Jan 3, 2022

Study contacts

Chenghai Liu
study director · Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fuzheng huayu

Start the discussion